Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $51.5M | $50.9M | $210.0M | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $51.5M | $50.9M | $210.0M | $0 | $0 | $0 | $0 | $0 |
| Gross margin | 100.0% | 100.0% | 100.0% | — | — | — | — | — |
| R&D | $131.0M | $196.3M | $66.3M | $41.7M | $39.6M | $62.8M | $85.1M | $117.0M |
| Operating income | −$123.5M | −$195.6M | $108.0M | −$65.3M | −$61.3M | −$88.7M | −$114.8M | −$189.9M |
| EBITDA | −$121.8M | −$193.1M | $112.3M | $62.2M | −$56.7M | −$87.6M | −$114.7M | −$182.8M |
| Net income | −$105.7M | −$193.4M | $114.2M | $63.1M | −$58.9M | −$84.5M | −$114.2M | −$175.7M |
| Net margin | -205.3% | -379.9% | 54.4% | — | — | — | — | — |
| EPS (diluted) | -3.06 | -5.45 | 3.17 | 1.70 | -1.39 | -1.14 | -1.12 | -1.45 |
Annual figures · source: Financial Modeling Prep
No one on the platform currently holds ISEE.
No tracked institution reports a position in ISEE as of their last filing.
No one on the platform has traded ISEE yet.
| $8.2B |
| — |
| LHCGLHC Group, Inc. | $169.81 | +0.00% | $5.3B | — |
| MRTXMirati Therapeutics, Inc. | $58.70 | -0.17% | $4.1B | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
$LCTX Astellas paid 5.9 billion for $ISEE and Biogen paid 5.6 billion for $APLS those are slow it down drugs
View on StockTwits ↗$CYTK got its long awaited approval last Friday after the close. Attached is a worksheet that compares CYTK's valuation as a multiple of 10-year analyst consensus revenue estimates versus 4 peer M&A exits (peers being those with similar revenue projections). We do not have any information on CYTK's anticipated gross profit margin but the 4 peers forecast gross margins in the mid-90s. On first glance it appears CYTK's valuation appears a tad rich when compared to M&A valuations of peers like $ISEE & $VRNA with similar 10-year revenue projections. Any CYTK pipeline valuation would/should manifest in longer term revenue forecasts. We do not know much about CYTK & would appreciate sincere perspectives from those that do. We read rumors from 18 months ago that Novartis was considering buying CYTK for $100/share. Should CYTK have accepted the offer (if it was even real)? This is not investment advice. We genuinely want pro-CYTK perspectives. This is not investment advice. $XBI $IBB
View on StockTwits ↗$ISEE "L"ets "F" "S"horts 🩳🔥🩳🔥🔥🩳🖕🩳🔥🔥✅🔜🕖 Ever get bullied??? Trading stocks?? Me too!!! Get the bullies out of the schools 🏫 The IPO Foreign Meme movement ***LFS***
View on StockTwits ↗@qwertylicious2003 @Ablidy look at the timeline of GATHER 1 & GATHER 2 studies for Iveric and look at the $isee stock chart. Shows their path and price appreciation
View on StockTwits ↗$LCTX This is why they aren't selling the company. Remember when $ISEE was bought for 5.9 billion for 1 terrible drug that barely works? They know this. They know what they have is also a paradigm shift in medicine for MANY indications, not just Dry AMD. If what they have works better than Zimura (which it does) than this company post phase 3 is worth over 5.9 billion. Unless this trades at a 4 billion market cap tomorrow they aren't considering a buyout ANYTIME SOON so stop dreaming fellas. Market cap needs to get there first. Companies do not get bought out for 6 billion + when they trade at a 250 million market cap.... It needs to re-rate BIG before any buyout discussions take place. The only scenario where i see potential for a buyout is if we keep heading up big near term and Genentech offers like 3 billion SOON like next year. Right after phase 2A while its still early. I highly doubt acquisitions are going to be considered they will want the right price for it, that takes time.
View on StockTwits ↗@pThebee look at the $ISEE chart. You're right AFTER phase 2 it started running up to its eventual buyout valuation P-BEE.
View on StockTwits ↗@pThebee if $ISEE was bought for 5.9 billion a company with ONE Dry AMD drug (and nothing else) that doesn't even improve vision and barely slows it down... then this is worth MORE. They have an entire cell therapy platform P-BEE. You already know this!
View on StockTwits ↗$ISEE IVERIC bio, Inc. (ISEE): Promising Ophthalmology Pipeline Overshadowed by Mounting Losses https://beyondspx.com/article/iveric-bio-inc-isee-promising-ophthalmology-pipeline-overshadowed-by-mounting-losses
View on StockTwits ↗@MasterShorts20 did you also see the troth with $ISEE and $TSLA 😂
View on StockTwits ↗$ICU $ISEE $SMMT $SPY $TNON Compliance PR from GLMD .. let’s double ✈️✈️
View on StockTwits ↗$SMMT $TNON $ICU $ISEE $SPY Next up GLMD don’t sleep on me
View on StockTwits ↗Next big idea GLMD I gave $SMMT at 1.20 and it’s currently trading over 30.00 I gave $TNON under 2.00 and it just went over 100.00 a share Friday. I gave $ICU under 1.00 and it’s now trading over 5.00 I gave $ISEE around 14.00 and even lower and it’s now trading over 40.00 https://x.com/tt_stocks_/status/1835349173551366480?s=46
View on StockTwits ↗@TheUrbanFarmer @AnchorMB Astellas bought $ISEE ( Opus own some rights ) for $6B.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.